Pharmacokinetics of nevirapine in HIV-infected infants weighing 3kg to less than 6kg taking paediatric fixed dose combination tablets

AIDS

Volumn 26, Issue 14, 2012, Pages 1795-1800

  Fillekes, Quirine ^a   Mulenga, Veronica ^b   Kabamba, Desiré ^b   Kankasa, Chipepo ^b   Thomason, Margaret J ^c   Cook, Adrian ^c   Ferrier, Alex ^c   Chintu, Chifumbe ^b   Walker, A Sarah ^c   Gibb, Diana M ^c   Burger, David M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

children; fixed dose combination; nevirapine; pharmacokinetics; Zambia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE; TRIOMUNE BABY; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFANT; MALE; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; TABLET FORMULATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HIV SEROPOSITIVITY; HUMANS; INFANT; INFANT, NEWBORN; LAMIVUDINE; MALE; NEVIRAPINE; STAVUDINE; VIRAL LOAD; ZAMBIA;

EID: 84866315505     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835705fd     Document Type: Article

References (27)

1. World Health Organisation. Antiretroviral therapy of HIV infection in infants and children: Towards universal access. Recommendations for a public health approach: 2010 revision. Geneva, World Health Organisation, 2010. http://www.who. int/hiv/pub/paediatric/infants2010/en/index.html. [Accessed on 1 December 2011].
2. Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42:599-605. (Pubitemid 36805618)
3. Ellis JC, L'Homme RFA, Ewings FM, Mulenga V, Bell F, Chileshe R, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12:253-260. (Pubitemid 46569910)
4. L'Homme RF, Kabamba D, Ewings FM, Mulenga V, Kankasa C, Thomason MJ, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22:557-565. (Pubitemid 351640588)
5. Pollock L, Else L, Poerksen G, Molyneux E, Moons P, Walker S, et al. Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. J Antimicrob Chemother 2009; 64:1251-1259.
6. Swaminathan S, Ramachandran G, Agibothu Kupparam HK, Mahalingam V, Soundararajan L, Perumal Kannabiran B, et al. Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India. J Antimicrob Chemother 2011; 66:1354-1359.
7. Poerksen G, Pollock L, Moons P, Chesshyre E, Burger D, Khoo S, et al. Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. Antivir Ther 2010; 15:343-350.
8. EMA. Viramune 200mg tablets; Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/docu ment-library/EPAR-Product-Information/ human/000183/WC500051481.pdf. [Accessed on 1 December 2011].
9. Mulenga V, Cook A, Walker AS, Kabamba D, Chijoka C, Ferrier A, et al. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination 'baby pills' in Zambia: a randomized controlled trial. Clin Infect Dis 2010; 51:1081-1089.
10. World Health Organisation. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach-2010 revision. Annex E. pp. 101-154. http://www.who.int/hiv/pub/ paediatric/infants 2010/en/index.html. [Accessed on 1 December 2011].
11. Burger D, Ewings F, Kabamba D, L'Homme R, Mulenga V, Kankasa C, et al. Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets. Ther Drug Monit 2010; 32:369-372.
12. Hollanders RMW, van Ewijk-Beneken Kolmer EWJ, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Determination of nevir-apine, an HIV-1 nonnucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000;744:65-71. (Pubitemid 30412051)
13. Verweij-van Wissen CP, Aarnoutse RE, Burger DM. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816:121-129. (Pubitemid 40143498)
14. Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, et al. Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J 2006; 25:420-426.
15. EMA. Epivir; 150 mg film-coated tablets. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/docu-ment-library/EPAR- Product-Information/human/000107/WC500027572.pdf. [Accessed on 1 December 2011].
16. EMA. Zerit; 15mg hard capsule. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/doc ument-library/EPAR-Product-Information/ human/000110/WC500049165.pdf. [Accessed on 1 December 2011].
17. World Health Organisation. Preferred antiretroviral medicines for treating and preventing HIV infection in younger children. http://www.who.int/ hiv/pub/paediatric/ARV-WG-meeting- report-may2008.pdf. [Accessed on December 2011].
18. Sumpter A, Anderson BJ. Pediatric pharmacology in the first year of life. Curr Opin Anaesthesiol 2009; 22:469-475.
19. Anderson GD. Developmental pharmacokinetics. Semin Pediatr Neurol 2010; 17:208-213.
20. Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, Altan AM, et al. Nevirapine-induced hepatotoxicity and pharmaco-genetics: a retrospective study in a population from Mozambique. Pharmacogenomics 2010; 11:23-31.
21. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007; 8:86-91. (Pubitemid 46390844)
22. Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43:783-786. (Pubitemid 44330746)
23. Duong M, Buisson M, Peytavin G, Kohli E, Piroth L, Martha B, et al. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann Pharmacother 2005; 39:603-609. (Pubitemid 40396611)
24. Gonzalez de Requena D, Bonora S, Garazzino S, Sciandra M, D'Avolio A, Raiteri R, et al. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother 2005; 49:3966-3969. (Pubitemid 41233062)
25. Gonzalezde Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16:290-291. (Pubitemid 34118577)
26. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268. (Pubitemid 32592358)
27. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 (Suppl 1):S21-S33. (Pubitemid 37158630)